Table 1.
Basic characteristics of the TAO patients and GD patients.
| Variable | TAO | GD (n = 25) |
P value | ||
|---|---|---|---|---|---|
| Active TAO (n = 30) |
Inactive TAO (n = 25) |
TAO vs. GD | Active vs. Inactive | ||
| Age, y | 49.53 ± 1.87 | 45.48 ± 3.04 | 45.24 ± 3.16 | 0.49* | 0.35* |
| Female gender, n (%) | 19 (63.33) | 15 (60.00) | 15 (60.00) | 0.62# | 0.80# |
| Smoke, n (%) | 9 (30.00) | 1 (4.00) | 1 (4.00) | 0.18# | 0.03# |
| FT3 | 4.11 ± 0.65 | 3.95 ± 0.21 | 3.35 ± 0.67 | 0.24※ | 0.08※ |
| FT4 | 1.16 ± 0.20 | 1.14 ± 0.11 | 0.84 ± 0.08 | 0.59※ | 0.22※ |
| TSH | 2.75 ± 1.15 | 2.36 ± 1.16 | 2.14 ± 0.46 | 0.32※ | 0.29※ |
| TRAb | 13.56 ± 4.05 | 13.77 ± 2.33 | 3.67 ± 1.64 | 0.01※ | 0.65※ |
| CAS | 3.93 ± 0.19 | 1.44 ± 0.10 | NA | NA | <0.01※ |
GD Grave’s disease patients without ophthalmopathy, FT3 Free triiodothyronine, FT4 Free thyroxine, TSH Thyroid stimulating hormone, TRAb Thyrotrophin receptor antibody, NA no available.
*P compared by Independent-sample t test; ※P compared by Mann–Whitney test; #P compared by chi‐square test or Fisher exact test. Significant at p < 0.05.